CEL-SCI (CVM) Receives $3 Million From Warrant Exercises
4/29/2014 9:44:57 AM
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it has received approximately $3 million through the exercise of warrants by investors to purchase the Company's common stock over the past 45 days. These $3 million are in addition to the $10 million raised in a public offering that closed on April 17, 2014. Proceeds from the warrant exercises and the public offering will be used to fund CEL-SCI’s Phase III head and neck cancer clinical trial, other research and development, and general and administrative expenses.
Help employers find you! Check out all the jobs and post your resume.
comments powered by